Drug Profile
Research programme: inhaled vancomycin - Nektar Therapeutics
Alternative Names: NKTR-063Latest Information Update: 02 Dec 2021
Price :
$50
*
At a glance
- Originator Nektar Therapeutics
- Class Antibacterials; Glycopeptides; Peptide antibiotics
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Gram-positive infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Gram-positive-infections in USA (PO, Inhalant)
- 09 Jan 2009 Preclinical trials in Gram-positive infections in USA (PO)